Kaleido Biosciences, Inc. (KLDO)

0.0001 0.0000 (0.00%) At close: 03:24PM EDT

Kaleido Biosciences, Inc.

65 Hayden Avenue
Lexington, MA 02421
United States
617 674 9000
https://kaleido.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 76

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Kimberly Hocknell	Senior Vice President of Technical Operations	N/A	N/A	N/A
Dr. Mark A. Wingertzahn Ph.D.	Senior VP of R&D and Head of Development	N/A	N/A	1972

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Corporate governance

Kaleido Biosciences, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.